What is Vicapsys Life Sciences Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vicapsys Life Sciences's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.18.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Vicapsys Life Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Vicapsys Life Sciences's Cash-to-Debt or its related term are showing as below:
VICP'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18 Med: No Debt Max: No Debt
Current: 0.18
During the past 6 years, Vicapsys Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.18. And the median was No Debt.
Vicapsys Life Sciences Cash-to-Debt Historical Data
The historical data trend for Vicapsys Life Sciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Vicapsys Life Sciences Cash-to-Debt Chart
|
Vicapsys Life Sciences Annual Data
|
|
Trend |
Dec08 |
Dec09 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
0.04 |
No Debt |
No Debt |
No Debt |
No Debt |
|
Vicapsys Life Sciences Quarterly Data
|
|
Jun10 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
No Debt |
No Debt |
No Debt |
0.88 |
0.18 |
Competitive Comparison of Vicapsys Life Sciences's Cash-to-Debt
For the Biotechnology subindustry, Vicapsys Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicapsys Life Sciences's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicapsys Life Sciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vicapsys Life Sciences's Cash-to-Debt falls into.
Vicapsys Life Sciences Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Vicapsys Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
Vicapsys Life Sciences had no debt (1).
Vicapsys Life Sciences's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description
Traded in Other Exchanges
N/A
Address
7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
Executives
| Moore Bobby M Jr |
10 percent owner |
4125 S.B. MERRION ROAD, LAKELAND FL 33810 |
| Robert Grammen |
10 percent owner |
9180 GALLENA COURT, NAPLES FL 34109 |
| Michael Yurkowski |
director |
1505 ELM STREET, #1504, DALLAS TX 75201 |
| William P. Esping |
10 percent owner |
2828 ROUTH STREET, SUITE 500, DALLAS TX 75201 |
| Rodger Rees |
director |
C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432 |
| Mark Feldmesser |
director |
641 UNIVERSITY BLVE, JUPITER FL 33458 |
| Federico Pier |
director |
1004 PLUM DRIVE, IRVING TX 75063 |
| Ryan Seddon |
director, 10 percent owner |
8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411 |
Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VICP has been successfully added to your